Investment
Features
FeesSafety
Academy
More
Pluang+

Compare abrdn Income Credit Strategies Fund (ACP) vs Smith & Nephew plc (SNN) Price & Performance

abrdn Income Credit Strategies FundTrade
Smith & Nephew plcTrade

Price performance (Past 24H)

Key statistics

abrdn Income Credit Strategies Fund vs Smith & Nephew plc — how do they compare? abrdn Income Credit Strategies Fund trades at $5.15 (market cap $641.16M), while Smith & Nephew plc trades at $29.76 (market cap $12.54B). The key difference: Smith & Nephew plc is far larger — about 19.6× abrdn Income Credit Strategies Fund's market cap, and abrdn Income Credit Strategies Fund pays the higher dividend (18.2%). Which is the better fit depends on your goals.

ACPSNN
Market Cap
$641.16M$12.54B
Sector
FinancialsHealth
52-Week High
$5.98$38.70
52-Week Low
$5.01$28.73
Dividend Yield
18.2%2.65%
Enterprise Value
$15.57B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

abrdn Income Credit Strategies Fund

ACP trades at $5.14, up 1.18% today, with a bearish technical signal from moving averages. The stock shows a low P/E of 7.74 and P/B of 0.9, indicating potential undervaluation, while a high net income margin of 95.31% and consistent dividend payments highlight financial strength. Recent news confirms dividend declarations for 2026.

The outlook is mixed; attractive valuation and dividends offer opportunity, but volatile revenue, an unsustainable distribution rate flagged by analysts, and high leverage pose significant risks. Investor sentiment is cautious due to these fundamental concerns.

Smith & Nephew plc

Smith & Nephew (SNN) trades at $29.76, down 1.06% with bearish technical signals. The company shows improving fundamentals with revenue growth from $5.8B to $6.2B and net income margin expanding to 10.08% in 2025. Recent Q2 2026 earnings beat expectations but the company lowered full-year revenue guidance from 6% to 4% growth due to U.S. Orthopaedics weakness.

While valuation multiples appear reasonable (P/E 20.41, EV/EBITDA 9.9), the stock faces headwinds from mixed earnings performance and cautious analyst sentiment. The primary investment case hinges on execution in robotics and wound care segments offsetting orthopedic challenges, with downside risk from continued U.S. market softness.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About abrdn Income Credit Strategies Fund

abrdn Income Credit Strategies Fund is a diversified, closed-end investment management company. Its primary goal is to generate high current income, with capital appreciation as a secondary objective. The fund mainly invests in debt and loan instruments from issuers across various industries and regions.

Read more on ACP

About Smith & Nephew plc

Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions. Roughly 42% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 28% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.

Read more on SNN